NR566 / NR 566
Final Exam Review
Study Guide
Latest 2026/2027 Edition
Advanced Pharmacology
for Care of the Family
Chamberlain University
College of Nursing | Graduate Nursing Program
150 Comprehensive Practice Questions
with Detailed Answers & Rationales
Aligned with Chamberlain NR566 Course Syllabus,
AACN Essentials of Master's Education, and
Advanced Pharmacology Competencies
,NR566 Final Exam Review Study Guide - Advanced Pharmacology for Care of the Family Chamberlain University | 2026/2027 Edition
Examination Overview & Test-Taking Guidance
Welcome to the NR566 Final Exam Review Study Guide. This comprehensive examination preparation
resource has been developed to align with the Chamberlain University NR566 Advanced Pharmacology for
Care of the Family course syllabus, the AACN Essentials of Master's Education for Advanced Nursing
Practice, and the 2026/2027 Advanced Pharmacology Competencies. The guide contains 150
multiple-choice questions distributed across ten core pharmacology domains, with 75% of items written in
a scenario-based format reflecting authentic clinical encounters, and 25% as direct knowledge questions
testing foundational pharmacological principles. Each item includes a detailed rationale explaining why the
correct response is best and why the distractors are incorrect, with explicit reference to advanced
pharmacology principles and NR566 curriculum standards. The cognitive level distribution targets 20%
recall, 50% application, and 30% analysis questions to mirror the rigor of the actual final examination and
to promote clinical reasoning development appropriate for the advanced practice nurse.
Cognitive Level Percentage Question Count
Recall (Knowledge) 20% 30 questions
Application 50% 75 questions
Analysis (Clinical Reasoning) 30% 45 questions
TOTAL 100% 150 questions
Section Topic Questions
Section 1 Pharmacokinetics & Pharmacodynamics 15 questions
Section 2 Pharmacogenomics & Personalized Medicine 10 questions
Section 3 Cardiovascular Pharmacology 20 questions
Section 4 Respiratory Pharmacology 12 questions
Section 5 Endocrine Pharmacology 18 questions
Section 6 Gastrointestinal & Renal Pharmacology 15 questions
Section 7 Neurological & Psychopharmacology 15 questions
Section 8 Anti-infective Pharmacology 12 questions
Section 9 Special Populations & Lifespan Considerations 18 questions
Section 10 Comprehensive Case Studies & Medication Management 15 questions
TOTAL 150 questions
NR566 - Advanced Pharmacology for Care of the Family Page 2
,NR566 Final Exam Review Study Guide - Advanced Pharmacology for Care of the Family Chamberlain University | 2026/2027 Edition
Section 1: Pharmacokinetics & Pharmacodynamics
Q1: A 68-year-old patient with hepatic cirrhosis is prescribed a drug with a high first-pass effect. The provider
orders conversion from oral to intravenous administration. Which pharmacokinetic change is most expected
when switching from the oral to the IV route?
A. The drug's bioavailability will decrease significantly due to bypassing the gut.
B. The drug's bioavailability will increase to approximately 100% because hepatic first-pass metabolism
is bypassed. [CORRECT]
C. The drug's half-life will decrease by 50% due to faster renal excretion.
D. The drug's protein binding will increase due to reduced albumin production.
Correct Answer: B
Rationale: The first-pass effect describes hepatic metabolism of a drug before it reaches systemic circulation,
reducing oral bioavailability. The IV route bypasses both gut absorption and the portal circulation, so bioavailability
approaches 100%. Bioavailability cannot decrease when switching to IV, and half-life and protein binding are not
directly altered by route changes. This principle is central to NR566 dosing calculations and route selection.
Q2: A patient receives a drug that is 95% protein-bound with a volume of distribution of 8 L. The patient
develops hypoalbuminemia (albumin 2.0 g/dL). Which consequence is most likely?
A. Increased free drug levels, potentially causing toxicity even at standard doses. [CORRECT]
B. Decreased free drug levels due to enhanced protein binding.
C. No change in drug effect because only unbound drug is active.
D. Increased therapeutic efficacy without risk of toxicity due to faster elimination.
Correct Answer: A
Rationale: Hypoalbuminemia reduces the number of protein binding sites, increasing the free (active) fraction of
highly protein-bound drugs. This can produce toxicity even when total drug levels appear therapeutic. While only
unbound drug is pharmacologically active, total levels underestimate free drug in hypoalbuminemia, making dose
adjustment and monitoring of free levels necessary. This is a cornerstone principle in NR566 pharmacokinetics for
special populations.
Q3: A drug has a half-life of 12 hours and is administered once daily. Approximately how long will it take to
reach steady-state plasma concentration?
A. 12 hours (one half-life).
B. 24 hours (two half-lives).
C. 48 to 60 hours (approximately four to five half-lives). [CORRECT]
D. 144 hours (twelve half-lives).
Correct Answer: C
Rationale: Steady state is reached after approximately four to five half-lives of a drug, regardless of dosing interval.
For a drug with a 12-hour half-life, steady state is achieved in 48 to 60 hours. One or two half-lives are insufficient,
and waiting twelve half-lives is unnecessary. This concept underlies loading dose decisions and therapeutic drug
monitoring timing in NR566.
Q4: A drug with a narrow therapeutic index has a therapeutic range of 10 to 20 mcg/mL, with toxicity
occurring above 25 mcg/mL. The current level is 22 mcg/mL. Which interpretation is most accurate?
NR566 - Advanced Pharmacology for Care of the Family Page 3
, NR566 Final Exam Review Study Guide - Advanced Pharmacology for Care of the Family Chamberlain University | 2026/2027 Edition
A. Subtherapeutic; the dose should be increased.
B. Therapeutic; no change is needed.
C. Above therapeutic range; the next dose should be held and the prescriber notified. [CORRECT]
D. Within the therapeutic range; the level indicates effective dosing.
Correct Answer: C
Rationale: A level of 22 mcg/mL exceeds the upper therapeutic bound of 20 mcg/mL and approaches the toxic
threshold of 25 mcg/mL. For narrow-index drugs, levels above the therapeutic range warrant dose hold and
prescriber notification to prevent toxicity. Increasing the dose would be unsafe, and the level is neither therapeutic
nor subtherapeutic. This principle is foundational to NR566 therapeutic drug monitoring.
Q5: A patient is started on a loading dose of phenytoin. Which pharmacokinetic rationale best explains why a
loading dose is used?
A. To achieve immediate therapeutic plasma concentrations without waiting for steady state.
[CORRECT]
B. To bypass hepatic first-pass metabolism.
C. To reduce the risk of adverse drug reactions.
D. To increase the drug's half-life.
Correct Answer: A
Rationale: A loading dose rapidly achieves therapeutic plasma concentrations when waiting four to five half-lives
for steady state would be clinically unacceptable (e.g., seizures, arrhythmias, sepsis). It does not bypass first-pass
metabolism, does not inherently reduce adverse effects, and does not change the drug's half-life. The loading dose
principle is repeatedly emphasized in NR566 for narrow-index agents.
Q6: A drug is a full agonist at receptor sites with high intrinsic activity. Which statement best characterizes
this drug?
A. It binds receptors without producing any effect.
B. It produces a maximal response when enough receptors are occupied. [CORRECT]
C. It blocks the action of endogenous ligands.
D. It has lower efficacy than a partial agonist.
Correct Answer: B
Rationale: A full agonist has both high affinity and high intrinsic activity, producing a maximal response at full
receptor occupancy. Antagonists bind without activity, and partial agonists have lower intrinsic activity than full
agonists. Full agonists do not block endogenous ligands. NR566 receptor theory emphasizes these distinctions for
rational drug selection.
Q7: A patient has been taking lorazepam for several weeks and now requires a higher dose to achieve the
same anxiolytic effect. Which pharmacodynamic phenomenon is most likely occurring?
A. Tachyphylaxis, an acute loss of response.
B. Tolerance, a chronic decrease in response requiring dose escalation. [CORRECT]
C. Idiosyncratic reaction to the drug.
D. Cumulative toxicity from drug accumulation.
Correct Answer: B
NR566 - Advanced Pharmacology for Care of the Family Page 4
Final Exam Review
Study Guide
Latest 2026/2027 Edition
Advanced Pharmacology
for Care of the Family
Chamberlain University
College of Nursing | Graduate Nursing Program
150 Comprehensive Practice Questions
with Detailed Answers & Rationales
Aligned with Chamberlain NR566 Course Syllabus,
AACN Essentials of Master's Education, and
Advanced Pharmacology Competencies
,NR566 Final Exam Review Study Guide - Advanced Pharmacology for Care of the Family Chamberlain University | 2026/2027 Edition
Examination Overview & Test-Taking Guidance
Welcome to the NR566 Final Exam Review Study Guide. This comprehensive examination preparation
resource has been developed to align with the Chamberlain University NR566 Advanced Pharmacology for
Care of the Family course syllabus, the AACN Essentials of Master's Education for Advanced Nursing
Practice, and the 2026/2027 Advanced Pharmacology Competencies. The guide contains 150
multiple-choice questions distributed across ten core pharmacology domains, with 75% of items written in
a scenario-based format reflecting authentic clinical encounters, and 25% as direct knowledge questions
testing foundational pharmacological principles. Each item includes a detailed rationale explaining why the
correct response is best and why the distractors are incorrect, with explicit reference to advanced
pharmacology principles and NR566 curriculum standards. The cognitive level distribution targets 20%
recall, 50% application, and 30% analysis questions to mirror the rigor of the actual final examination and
to promote clinical reasoning development appropriate for the advanced practice nurse.
Cognitive Level Percentage Question Count
Recall (Knowledge) 20% 30 questions
Application 50% 75 questions
Analysis (Clinical Reasoning) 30% 45 questions
TOTAL 100% 150 questions
Section Topic Questions
Section 1 Pharmacokinetics & Pharmacodynamics 15 questions
Section 2 Pharmacogenomics & Personalized Medicine 10 questions
Section 3 Cardiovascular Pharmacology 20 questions
Section 4 Respiratory Pharmacology 12 questions
Section 5 Endocrine Pharmacology 18 questions
Section 6 Gastrointestinal & Renal Pharmacology 15 questions
Section 7 Neurological & Psychopharmacology 15 questions
Section 8 Anti-infective Pharmacology 12 questions
Section 9 Special Populations & Lifespan Considerations 18 questions
Section 10 Comprehensive Case Studies & Medication Management 15 questions
TOTAL 150 questions
NR566 - Advanced Pharmacology for Care of the Family Page 2
,NR566 Final Exam Review Study Guide - Advanced Pharmacology for Care of the Family Chamberlain University | 2026/2027 Edition
Section 1: Pharmacokinetics & Pharmacodynamics
Q1: A 68-year-old patient with hepatic cirrhosis is prescribed a drug with a high first-pass effect. The provider
orders conversion from oral to intravenous administration. Which pharmacokinetic change is most expected
when switching from the oral to the IV route?
A. The drug's bioavailability will decrease significantly due to bypassing the gut.
B. The drug's bioavailability will increase to approximately 100% because hepatic first-pass metabolism
is bypassed. [CORRECT]
C. The drug's half-life will decrease by 50% due to faster renal excretion.
D. The drug's protein binding will increase due to reduced albumin production.
Correct Answer: B
Rationale: The first-pass effect describes hepatic metabolism of a drug before it reaches systemic circulation,
reducing oral bioavailability. The IV route bypasses both gut absorption and the portal circulation, so bioavailability
approaches 100%. Bioavailability cannot decrease when switching to IV, and half-life and protein binding are not
directly altered by route changes. This principle is central to NR566 dosing calculations and route selection.
Q2: A patient receives a drug that is 95% protein-bound with a volume of distribution of 8 L. The patient
develops hypoalbuminemia (albumin 2.0 g/dL). Which consequence is most likely?
A. Increased free drug levels, potentially causing toxicity even at standard doses. [CORRECT]
B. Decreased free drug levels due to enhanced protein binding.
C. No change in drug effect because only unbound drug is active.
D. Increased therapeutic efficacy without risk of toxicity due to faster elimination.
Correct Answer: A
Rationale: Hypoalbuminemia reduces the number of protein binding sites, increasing the free (active) fraction of
highly protein-bound drugs. This can produce toxicity even when total drug levels appear therapeutic. While only
unbound drug is pharmacologically active, total levels underestimate free drug in hypoalbuminemia, making dose
adjustment and monitoring of free levels necessary. This is a cornerstone principle in NR566 pharmacokinetics for
special populations.
Q3: A drug has a half-life of 12 hours and is administered once daily. Approximately how long will it take to
reach steady-state plasma concentration?
A. 12 hours (one half-life).
B. 24 hours (two half-lives).
C. 48 to 60 hours (approximately four to five half-lives). [CORRECT]
D. 144 hours (twelve half-lives).
Correct Answer: C
Rationale: Steady state is reached after approximately four to five half-lives of a drug, regardless of dosing interval.
For a drug with a 12-hour half-life, steady state is achieved in 48 to 60 hours. One or two half-lives are insufficient,
and waiting twelve half-lives is unnecessary. This concept underlies loading dose decisions and therapeutic drug
monitoring timing in NR566.
Q4: A drug with a narrow therapeutic index has a therapeutic range of 10 to 20 mcg/mL, with toxicity
occurring above 25 mcg/mL. The current level is 22 mcg/mL. Which interpretation is most accurate?
NR566 - Advanced Pharmacology for Care of the Family Page 3
, NR566 Final Exam Review Study Guide - Advanced Pharmacology for Care of the Family Chamberlain University | 2026/2027 Edition
A. Subtherapeutic; the dose should be increased.
B. Therapeutic; no change is needed.
C. Above therapeutic range; the next dose should be held and the prescriber notified. [CORRECT]
D. Within the therapeutic range; the level indicates effective dosing.
Correct Answer: C
Rationale: A level of 22 mcg/mL exceeds the upper therapeutic bound of 20 mcg/mL and approaches the toxic
threshold of 25 mcg/mL. For narrow-index drugs, levels above the therapeutic range warrant dose hold and
prescriber notification to prevent toxicity. Increasing the dose would be unsafe, and the level is neither therapeutic
nor subtherapeutic. This principle is foundational to NR566 therapeutic drug monitoring.
Q5: A patient is started on a loading dose of phenytoin. Which pharmacokinetic rationale best explains why a
loading dose is used?
A. To achieve immediate therapeutic plasma concentrations without waiting for steady state.
[CORRECT]
B. To bypass hepatic first-pass metabolism.
C. To reduce the risk of adverse drug reactions.
D. To increase the drug's half-life.
Correct Answer: A
Rationale: A loading dose rapidly achieves therapeutic plasma concentrations when waiting four to five half-lives
for steady state would be clinically unacceptable (e.g., seizures, arrhythmias, sepsis). It does not bypass first-pass
metabolism, does not inherently reduce adverse effects, and does not change the drug's half-life. The loading dose
principle is repeatedly emphasized in NR566 for narrow-index agents.
Q6: A drug is a full agonist at receptor sites with high intrinsic activity. Which statement best characterizes
this drug?
A. It binds receptors without producing any effect.
B. It produces a maximal response when enough receptors are occupied. [CORRECT]
C. It blocks the action of endogenous ligands.
D. It has lower efficacy than a partial agonist.
Correct Answer: B
Rationale: A full agonist has both high affinity and high intrinsic activity, producing a maximal response at full
receptor occupancy. Antagonists bind without activity, and partial agonists have lower intrinsic activity than full
agonists. Full agonists do not block endogenous ligands. NR566 receptor theory emphasizes these distinctions for
rational drug selection.
Q7: A patient has been taking lorazepam for several weeks and now requires a higher dose to achieve the
same anxiolytic effect. Which pharmacodynamic phenomenon is most likely occurring?
A. Tachyphylaxis, an acute loss of response.
B. Tolerance, a chronic decrease in response requiring dose escalation. [CORRECT]
C. Idiosyncratic reaction to the drug.
D. Cumulative toxicity from drug accumulation.
Correct Answer: B
NR566 - Advanced Pharmacology for Care of the Family Page 4
